|
Chemotherapy - Updated Survival Data from TAX 327 Study: Docetaxel Plus
Prednisone Versus Mitoxanthrone Plus Prednisone for Advanced Prostate
Cancer. (JCO January 10, 2008)
(March 2008)
The updated data collected as of March 2007 reporting
median survival duration for the 1,006 men with metastatic
hormone-resistant prostate cancer continued to show superiority (P=.004)
for Docetaxel, 75 mg/m2 (D3P), given at three week intervals compared to
Mitoxanthrone (MP), 12 mg/m2 q 3 weeks: median survival 19.2 vs 16.3
months, respectively. For Docetaxel given weekly (D1P), 30 mg/m2, the
median survival was 17.8 months, which did not differ significantly from
the MP arm. Prednisone 5 mg BID was given in all arms.
Docetaxel given at
three week intervals "showed better palliation, with a higher
probability of pain and QOL response." The study continued to show that
patients on the weekly Docetaxel arm "were more likely to experience
early deterioration of QOL" and that median survival in this arm was not
significantly better than MP. Hence, the authors conclude that "weekly
docetaxel should not be adopted."
"The percentage of
patients who survived for more than 3 years in the D3P, D1P, and MP arms
were 18.6%, 16.8%, and 13.5% respectively."
The
authors concede that "Although the differences in median survival are
relatively small, they are accompanied by improvement in pain control
and QOL and are clinically meaningful ... [and] it seems reasonable to
offer treatment to patients with symptoms and to those who are likely to
develop symptoms in the near future."
«
Back to Article List
|
